BRIEF-Teva collaborates with Intel to develop a device for use in huntington disease
Sept 15 (Reuters) - Teva Pharmaceutical Ltd Says It Will Deploy The Technology Platform In A Sub
* Teva Pharmaceutical announces collaboration with Intel Corp to develop a unique wearable device and machine learning platform for use in huntington disease
* Study within ongoing Phase 2 Open-Pride HD study
* Says study will start towards end of year and will take place in centers in U.S and Canada Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.